Can AOD-9604 Reduce Lipogenesis Through C-Terminal Growth Hormone Activity Modulation? - Peptide Dosages

The title of this article poses a mechanism-level question, and mechanism-level questions deserve to be examined rather than assumed. The phrasing — whether AOD-9604 can reduce lipogenesis by modulating the C-terminal metabolic activity of growth hormone — bundles together three claims that are usually blurred in popular writing: that AOD-9604 has an antilipogenic action at all, that this action is inherited from a discrete C-terminal domain of human growth hormone, and that the domain works by “modulating” growth-hormone activity in a way that isolates fat handling from the hormone’s growth-promoting arm. Each of these has a different weight of evidence behind it, and treating them as a single settled fact is exactly the error this piece is written to avoid.

So rather than affirm the premise, we treat it as a research question with a real, if largely preclinical, evidence base. There genuinely is animal and cell data suggesting that the lipolytic C-terminal domain of growth hormone — and the stabilized synthetic fragment built from it — can inhibit key lipogenic enzymes and reduce the synthesis of new fat.23 But that data lives almost entirely in rodents and isolated fat tissue, the human obesity program built on it failed to beat placebo in its pivotal trial, and no study has ever measured de novo lipogenesis as an endpoint in humans given AOD-9604.110 The honest answer to the title is therefore “plausibly, in preclinical models, by a partially characterized mechanism — but not demonstrated in people, and not on the strength of an approved therapy.”

This piece is written for researchers and educated readers who want a precise map of what “reducing lipogenesis” would actually require, what the C-terminal-domain hypothesis really claims, and where the data stop. We will separate lipogenesis from lipolysis, unpack what “GH activity modulation” means at the receptor level, walk through the preclinical antilipogenic findings enzyme by enzyme, examine the β3-adrenergic link, weigh the human-evidence gap, compare AOD-9604 with agents that genuinely target the lipogenic pathway, review research methodology, and close with safety and regulatory status. The guiding principle throughout is restraint: AOD-9604 is not an approved therapy for obesity or any other condition, and nothing here should be read as suggesting it treats, cures, or prevents a disease.

Lipogenesis Is Not Lipolysis: Why the Distinction Decides the Question

Any serious discussion of whether AOD-9604 “reduces lipogenesis” has to begin by pinning down what lipogenesis is, because the word is routinely and incorrectly swapped for its opposite. The two processes sit on opposite sides of fat-cell metabolism and are governed by different enzymes and signals.

Lipolysis is the breakdown of stored triglyceride into glycerol and free fatty acids, released from the fat cell for use as fuel. Its rate-limiting machinery includes adipose triglyceride lipase and hormone-sensitive lipase, the latter activated when cyclic AMP rises and protein kinase A phosphorylates it. Most of the AOD-9604 literature — and most of its sibling articles on this site, such as the discussion of how AOD-9604 influences lipolysis without altering IGF-1 signaling — concerns this breakdown arm.

Lipogenesis is the reverse: the synthesis of fatty acids and their esterification into new triglyceride for storage. Its most-studied form, de novo lipogenesis (DNL), converts excess carbohydrate-derived carbon into fatty acids through a well-mapped enzymatic cascade. Citrate leaves the mitochondrion and is converted to acetyl-CoA; acetyl-CoA carboxylase (ACC) carboxylates it to malonyl-CoA; fatty acid synthase (FASN) then assembles malonyl-CoA units into the 16-carbon saturated fatty acid palmitate.12 The whole program is switched on by the transcription factors sterol regulatory element-binding protein-1c (SREBP-1c) and carbohydrate response element-binding protein (ChREBP), which are themselves driven by insulin and glucose.12 To “reduce lipogenesis” in any rigorous sense means to lower flux through this ACC–FASN axis, or to down-regulate the transcriptional program that feeds it.

This distinction is not pedantic; it decides the whole question. A compound could accelerate lipolysis while doing nothing to lipogenesis, or suppress lipogenesis while leaving lipolysis untouched. The claim embedded in this article’s title is specifically the second one — that AOD-9604 turns down the fat-building machinery — and it must be evaluated on its own evidence, not borrowed from the more heavily studied lipolytic arm. The table below fixes the contrast.

Net direction

Triglyceride → glycerol + free fatty acids

Acetyl-CoA / carbohydrate carbon → new fatty acids → triglyceride

Rate-limiting enzymes

ATGL, hormone-sensitive lipase

Acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN)12

Key regulators

Catecholamines, cAMP/PKA, β-adrenergic tone

Insulin, glucose, SREBP-1c, ChREBP12

What “more” does

Mobilizes stored fat for fuel

Expands stored fat

AOD-9604 claim

Stimulates it

Reduces it (the subject of this article)

Strength of AOD-9604 evidence

Preclinical, better characterized

Preclinical, thinner; no human flux data

Keeping the two columns separate is the single most useful habit for reading anything about this compound. When a vendor page says AOD-9604 “burns fat,” it is usually pointing at the left column; the title’s antilipogenic claim belongs to the right, and the right column is where the evidence is thinnest.

There is a further subtlety that makes the antilipogenic question especially hard to answer from outcome data alone. Net fat mass is the running balance of two opposing flows: fat coming in (lipogenesis plus dietary fat uptake) and fat going out (lipolysis plus oxidation). A shrinking fat depot is therefore compatible with several different mechanisms — more breakdown, less synthesis, or both — and body-weight or fat-mass endpoints cannot, by themselves, tell you which lever moved. This is why a study that reports “less fat” after AOD-9604 does not automatically establish “reduced lipogenesis”; it could just as well reflect accelerated lipolysis with lipogenesis unchanged. Isolating the antilipogenic contribution requires measuring the synthesis pathway directly — enzyme activity, lipogenic-gene expression, or isotopic tracer flux — rather than inferring it from the net result. Much of the confusion in popular writing about this compound comes from reading a net-fat-loss result as if it were a lipogenesis measurement, which it is not.

AOD-9604, the C-Terminal Domain, and What “GH Activity Modulation” Means

AOD-9604 is a synthetic 16-amino-acid peptide. Its name abbreviates “Anti-Obesity Drug 9604,” and its sequence corresponds to residues 176–191 of the C-terminal region of human growth hormone (hGH), with a tyrosine added at the N-terminus to improve stability and handling.1 Two cysteine residues form a disulfide bridge that reproduces the small loop found in the parent hormone’s lipolytic domain. The compound arose from work at Monash University in Melbourne and was developed commercially by Metabolic Pharmaceuticals Limited.

The phrase in this article’s title — “C-terminal growth hormone activity modulation” — deserves unpacking, because it encodes the entire scientific rationale behind the molecule. Full-length growth hormone is a 191-residue protein that does many things at once: it binds the growth-hormone receptor to trigger JAK2/STAT5 signaling, drives longitudinal bone growth, raises circulating IGF-1, and, through a mixture of receptor-dependent and possibly domain-localized effects, alters lipid metabolism. Decades of structure-function work sought to map which parts of the hormone carry which activities. Researchers localized much of the lipid-metabolic action — both the pro-lipolytic and the antilipogenic effects — to the C-terminal portion of the molecule.3 The design bet behind AOD-9604 was that a short peptide reproducing only that region could deliver the hormone’s fat-metabolic signal while leaving the growth-promoting, IGF-1-raising receptor signaling behind.

“Modulation” is therefore the operative and honest word. AOD-9604 is not proposed to activate the full growth-hormone receptor cascade; if it did, it would raise IGF-1 and impair glucose tolerance, the very effects it was engineered to avoid, and which it was repeatedly reported not to produce.1 Instead the hypothesis is that the C-terminal domain accesses fat-metabolic control by a route that is at least partly uncoupled from the classical receptor — a selective reproduction of one slice of growth-hormone biology. This is why it is more accurate to speak of the fragment modulating a specific arm of GH activity than of it “acting like growth hormone.” Readers who want the deeper metabolic-study context can consult the site’s overview of how AOD-9604 works in lipolysis and metabolic studies.

It helps to hold three levels distinct: the parent hormone (full-length hGH, broad endocrine effects including growth and IGF-1), the C-terminal lipid-metabolic domain (the region thought to carry lipolytic and antilipogenic signals), and the engineered fragment (AOD-9604, a stabilized reproduction of that domain). Each step narrows the biology. The antilipogenic question this article asks concerns only the middle level — whether the domain genuinely suppresses fat synthesis — and whether the fragment faithfully reproduces it. Collapsing the three levels back together, and reasoning “growth hormone affects fat, so this fragment must too, in exactly the parent’s way,” is precisely the shortcut that produces overconfident claims.

The Antilipogenic Hypothesis: What Growth Hormone Does to Fat Synthesis

Before evaluating the fragment, it is worth being clear about what the parent hormone is thought to do, because the C-terminal-domain hypothesis inherits its plausibility from that biology. Growth hormone’s effects on adipose tissue are complex and, in places, genuinely contested. Its best-established fat action is lipolytic: chronic GH exposure increases the mobilization and oxidation of stored fat, which is part of why growth-hormone deficiency is associated with increased fat mass and GH replacement reduces it.13

The antilipogenic side of the story is subtler. In several experimental systems, growth hormone has been reported to reduce the activity of lipogenic enzymes and to blunt insulin’s stimulation of fat synthesis in adipocytes, an effect sometimes described as part of GH’s “diabetogenic” and lipid-partitioning profile.13 In whole-body terms, GH tends to shift substrate use toward fat oxidation and away from fat storage. If a discrete C-terminal domain carries this antilipogenic signal, then a peptide reproducing that domain might inhibit lipogenic enzymes without the receptor-mediated growth effects — which is exactly the claim the AOD program set out to test.

Two cautions belong here. First, growth hormone’s antilipogenic effect in the parent hormone is entangled with its effects on insulin signaling; because insulin is the master driver of lipogenesis through SREBP-1c, anything that induces insulin resistance will secondarily reduce insulin-stimulated fat synthesis.1213 A key selling point of AOD-9604, however, is that it does not impair insulin sensitivity.1 That is metabolically attractive, but it also means AOD-9604 cannot be borrowing the parent hormone’s insulin-resistance route to suppress lipogenesis; any antilipogenic action it has would need to be more direct. Second, “growth hormone reduces lipogenesis” is itself a generalization with exceptions across species and tissues, so treating it as a firm platform on which the fragment’s claim rests would overstate the foundation.

It is also worth noting where in the body lipogenesis matters most, because it shapes what an antilipogenic peptide would and would not accomplish. In humans, the liver is the dominant site of de novo lipogenesis, particularly under high-carbohydrate conditions, while adipose-tissue DNL contributes a smaller fraction of total fat synthesis in most adults.12 The AOD-9604 preclinical enzyme data, however, come from adipose tissue, not liver. So even if one accepts that the fragment inhibits adipocyte lipogenic enzymes, the quantitative importance of that effect for whole-body fat balance in a human is uncertain, and it might differ substantially from what a hepatic-DNL inhibitor achieves. An honest account of the antilipogenic hypothesis has to flag this tissue mismatch: the compartment where the effect was demonstrated is not the compartment that drives most human de novo lipogenesis.

The upshot is a hypothesis with reasonable mechanistic motivation but built on a parent-hormone biology that is itself only partly settled. That is the appropriate starting posture: the antilipogenic idea is plausible enough to have driven a real drug-development program, not so established that it can be asserted as fact.

What the Preclinical Data Actually Show About Reduced Lipogenesis

This is the heart of the matter, and it is where the evidence is most concrete — while still being entirely preclinical. The strongest primary support for an antilipogenic action comes not from AOD-9604 itself but from its close structural sibling AOD9401, an earlier synthetic domain analogue studied by the same Monash group. In a study of Zucker fatty rats, AOD9401 was shown to stimulate hormone-sensitive lipase (the lipolytic arm) and, crucially for this article, to inhibit acetyl-CoA carboxylase — the rate-limiting enzyme of de novo lipogenesis — in isolated rat adipose tissue.2 Chronic treatment over 20 days reduced mean adipocyte diameter from roughly 110 to 80 micrometers and cut body-weight gain, without inducing the insulin resistance seen with intact growth hormone.2 A reduction in ACC activity is a direct, enzyme-level readout of suppressed lipogenesis; this is the most literal evidence in the AOD literature that a C-terminal hGH fragment can turn down the fat-building machinery.

A parallel oral-administration study reinforced the picture. A synthetic C-terminal hGH fragment was reported to have “lipolytic and antilipogenic activity similar to that of the intact hormone,” and oral treatment of genetically obese (ob/ob) mice for 30 days significantly slowed body-weight gain relative to controls.3 The explicit pairing of “lipolytic and antilipogenic” is important: it tells us the developers viewed suppression of fat synthesis as a genuine, measured component of the domain’s action, not an afterthought.

The foundational AOD-9604 metabolic paper by Ng and colleagues then established that the specific 176–191 fragment reproduced the lipolytic and fat-oxidizing actions of hGH in fat tissue and obese-rodent models, increased lipolytic activity in adipose tissue, and did so without raising IGF-1 or impairing insulin sensitivity.1 Chronic-treatment studies in obese and lean mice extended this to whole-body energy balance, showing increased fat oxidation, higher plasma glycerol (an index of lipolysis), and reduced fat mass.45

Pulling the antilipogenic thread together honestly requires three qualifications. First, the clearest enzyme-level antilipogenic finding (ACC inhibition) is from AOD9401, a related analogue, not from AOD-9604 itself; it is fair to treat the two as members of one C-terminal-domain family, but it is not the same as a dedicated ACC or FASN study on AOD-9604. Second, all of this is rodent and ex-vivo work — Zucker rats, ob/ob mice, isolated fat pads — with no human lipogenesis measurements. Third, the antilipogenic arm is consistently reported alongside, and is harder to disentangle from, the better-characterized lipolytic arm; net fat loss in these models reflects both a push toward breakdown and a pull away from synthesis, and the studies rarely isolate the two cleanly. The table below summarizes the concrete preclinical readouts.

Zucker fatty rats; isolated adipose tissue

AOD9401 (sibling domain analogue)

Inhibited acetyl-CoA carboxylase; stimulated HSL; adipocyte diameter 110→80 µm

2

ob/ob mice; oral, 30 days

Synthetic C-terminal hGH fragment

Described as “lipolytic and antilipogenic”; slowed weight gain

3

Obese Zucker rats; oral, 19 days

AOD9604

>50% reduction in body-weight gain; increased adipose lipolytic activity; no insulin-sensitivity harm

1

Obese & lean mice; osmotic pump, 14 days

Increased fat oxidation, plasma glycerol; reduced fat mass; β3-AR RNA restored

45

It is worth pausing on why the acetyl-CoA carboxylase finding is mechanistically satisfying, because it explains the enduring appeal of the antilipogenic hypothesis. ACC is not a peripheral enzyme; it catalyzes the committed, rate-limiting step of de novo lipogenesis, converting acetyl-CoA to malonyl-CoA.12 Malonyl-CoA sits at a metabolic crossroads: it is both the building block that fatty acid synthase polymerizes into palmitate and an allosteric inhibitor of carnitine palmitoyltransferase-1, the gatekeeper that admits fatty acids into mitochondria for oxidation. Lowering ACC activity therefore does two complementary things at once — it starves the synthesis pathway of substrate and, by reducing malonyl-CoA, releases the brake on fat oxidation. An agent that genuinely inhibits ACC would thus be expected to shift a fat cell from a storing to an oxidizing posture, which is precisely the whole-body phenotype reported for AOD-9604 in rodents (increased fat oxidation, reduced fat mass).5 The internal consistency between the enzyme finding for the sibling analogue and the whole-animal readouts for AOD-9604 is part of why the hypothesis is taken seriously, even though it remains preclinical.

Consistency, however, is not proof, and two gaps deserve emphasis. The ACC result has not been independently replicated for AOD-9604 itself with modern methods, nor extended to fatty acid synthase or to the upstream transcriptional regulators SREBP-1c and ChREBP that ultimately set lipogenic capacity.12 Without those data, we know that a related peptide lowered one lipogenic enzyme’s activity in rat fat tissue two decades ago, and we infer that AOD-9604 does something similar — but we do not have a full molecular map of how the fragment engages the lipogenic program, whether the effect is transcriptional or post-translational, or how large it is relative to the compound’s lipolytic action. The antilipogenic story is coherent and mechanistically motivated; it is not yet a completed picture.

So the fair verdict on the preclinical antilipogenic question is: yes, there is real, enzyme-level evidence that C-terminal hGH domain peptides can inhibit lipogenesis in rodent fat tissue, and AOD-9604 sits within that family — but the most direct antilipogenic readout is from a sibling analogue, the work is entirely preclinical, and the effect has never been isolated or quantified in humans.

The β3-Adrenergic Link and the Receptor-Level Picture

A recurring claim is that AOD-9604 works by directly engaging the beta-3 adrenergic receptor (β3-AR) on fat cells to raise cyclic AMP. This needs care, because it is both partly supported and frequently overstated, and because it is often applied to the lipogenic side when the evidence really concerns the lipolytic/energy-expenditure side.

The strongest primary evidence for β3-AR involvement comes from a study in which chronic treatment with hGH and with AOD-9604 failed to reduce body weight or increase lipolysis in β3-AR knockout mice, whereas it worked in wild-type controls.4 The same body of work found that both hGH and AOD-9604 restored the repressed levels of β3-AR messenger RNA in obese mice toward the levels seen in lean animals — a change in receptor expression rather than a simple binding event.4 Intriguingly, acute increases in energy expenditure and fat oxidation were still observed in the knockout animals, implying at least one β3-independent component to the acute response.5

How does this bear on lipogenesis specifically? β3-adrenergic signaling classically drives lipolysis and thermogenesis through cAMP and protein kinase A. Its connection to reduced lipogenesis is more indirect: sustained cAMP tone and the shift toward fat oxidation can suppress the insulin-driven lipogenic program, and restoring β3-AR expression in obese fat tissue re-sensitizes it to catecholamine-driven mobilization. But the direct ACC-inhibition finding described earlier came from enzyme assays, not from β3 signaling per se, so the antilipogenic effect and the β3-adrenergic effect are best treated as related but not identical mechanisms. The popular shorthand that AOD-9604 “binds β3 to burn fat” compresses a more nuanced reality: the receptor appears necessary for the sustained metabolic effect, its expression is modulated by the peptide, and the molecular details of how the fragment engages the pathway remain incompletely resolved. Much of the confident receptor-level language circulating online traces to commercial rather than primary sources.

For the antilipogenic question, then, the receptor picture is supportive but not decisive: it explains how the compound could shift fat tissue toward a net-mobilizing, less-storing state, without pinning the suppression of lipogenic enzymes to a single validated receptor event. Researchers cataloging why this compound is studied in fat-tissue models can find the broader framing in the site’s discussion of why AOD-9604 is studied for adipose-tissue breakdown research models.

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

AOD-9604’s clinical record lives almost entirely in obesity, and understanding it is the fairest way to gauge whether any of the preclinical antilipogenic promise translated to people. The short version: it was tested seriously, in humans, at scale, and it did not deliver on its primary endpoint — and none of the human work measured lipogenesis at all.

Across development, AOD-9604 was studied in roughly six human clinical trials enrolling more than 900 participants in total, a tally that derives from the sponsor’s development-program summary rather than a single publication.10 The centerpiece early study, a 12-week Phase 2 evaluation in obese adults (METAOD005) using once-daily oral dosing across several dose arms, was encouraging: the 1 mg arm reportedly lost more weight than placebo, and the results generated optimistic press.10 But the pivotal, longer, more rigorously controlled 24-week study (METAOD006) — a randomized, double-blind, placebo-controlled, multicenter trial that is the single published RCT on the compound — found that the weight-loss difference between AOD-9604 and placebo did not reach statistical significance at the primary endpoint, especially against a background of intensive diet and exercise.10 Development as an obesity drug was terminated in 2007.

Two points matter for the antilipogenic question. First, every human study used weight and body-composition endpoints, plus safety and pharmacokinetic measures. None used the tools that actually quantify de novo lipogenesis in people — stable-isotope tracers (for example, deuterated water incorporation into palmitate), adipose or hepatic lipogenic-gene expression, or measured lipogenic flux. So even the human trials that exist are silent on whether AOD-9604 reduces fat synthesis; they measured the downstream outcome (weight), not the mechanism (lipogenesis), and the downstream outcome was not robustly positive. Second, the reassuring endocrine profile held up: the compound was reported not to raise IGF-1 and not to impair glucose tolerance, consistent with the “GH activity modulation” design.1

Trials

~6 studies, >900 participants total10

Pivotal design

24-week randomized, double-blind, placebo-controlled, multicenter (METAOD006); oral10

Primary endpoint

Weight difference vs placebo did NOT reach statistical significance10

Lipogenesis measured?

No — no DNL tracer, lipogenic-gene, or flux endpoints in any human study

Endocrine profile

No reported IGF-1 rise; no impaired glucose tolerance1

Outcome

Obesity development halted in 200710

The honest reading is stark: the compound’s best-evidenced outcome (fat loss in obesity) was itself not robustly demonstrated in humans, and its proposed mechanism (reduced lipogenesis) was never measured in humans at all. Extrapolating from “inhibited ACC in rat fat pads” to “reduces lipogenesis in people” is a leap across species, tissues, and measurement methods, with no human data on the far side. For a measured look at how the clinical results are often characterized, see the site’s summary of what clinical trials indicate about the fat-burning potential of AOD-9604.

How AOD-9604 Compares With Agents That Actually Target Lipogenesis

One of the clearest ways to locate AOD-9604 is to place it beside compounds that were built explicitly to suppress lipogenesis. The contrast is instructive not because AOD-9604 competes with these agents — it never entered clinical lipogenesis trials — but because it shows what a purpose-designed lipogenesis inhibitor looks like in mechanism and evidence.

ACC inhibitors (e.g., firsocostat)

Directly block acetyl-CoA carboxylase, the rate-limiting DNL enzyme

Human trials in NAFLD/NASH with measured DNL suppression

FASN inhibitors

Block fatty acid synthase assembly of palmitate

Clinical development in metabolic/oncology settings; direct target

Metformin (indirect)

AMPK activation → ACC phosphorylation/inhibition; lowers SREBP-1c

Extensive human data; reduces hepatic DNL indirectly

GLP-1 / dual agonists (indirect)

Improve insulin sensitivity, reduce substrate load and SREBP-1c drive

Large human trials; DNL reduction is a secondary/indirect effect

AOD-9604

C-terminal hGH domain; ACC inhibition shown for sibling analogue; β3-linked substrate shift

Preclinical only; no human DNL endpoint; pivotal obesity trial failed

The pattern is unmistakable. Agents with a genuine claim to reducing lipogenesis either hit the lipogenic enzymes directly (ACC, FASN inhibitors) or turn down the transcriptional/insulin drive (metformin, incretin agonists), and each has been tested in humans with lipogenesis-relevant endpoints. AOD-9604’s antilipogenic case rests on an enzyme finding in a sibling analogue, a plausible substrate-partitioning story, and rodent net-fat-loss data — with no human lipogenesis measurement and a failed pivotal outcome trial. That does not make it uninteresting as a research probe of C-terminal GH biology; it does mean it cannot be placed in the same evidentiary tier as compounds designed and tested to inhibit fat synthesis.

There is a further lesson embedded here. Even direct, purpose-built lipogenesis inhibitors have found the path to approved therapy difficult: potent ACC inhibition, for instance, can paradoxically raise circulating triglycerides by rerouting metabolism, illustrating how hard it is to translate a clean enzyme effect into a clinical benefit. A fragment whose antilipogenic action is indirect, largely inferred, and untested in humans starts far behind that already-difficult field.

It is also worth situating the antilipogenic question within the compound’s broader research trajectory, because that context guards against over-reading any single finding. After the obesity program ended, AOD-9604 reappeared in directions entirely unrelated to fat synthesis: most notably as an experimental intra-articular agent for osteoarthritis, where weekly injections improved cartilage scores in a rabbit model, alone or combined with hyaluronic acid.8 That cartilage result is a genuine, peer-reviewed preclinical finding, but it concerns a different tissue, delivery route, and biological question, and it cannot be borrowed to support the lipogenesis claim any more than the lipogenesis data can be borrowed to support a joint claim. The pattern across the compound’s history is a recurring one: promising signals in narrow preclinical settings that have not been consolidated into any approved human use. The antilipogenic hypothesis should be read as one more entry in that pattern — mechanistically interesting, preclinically supported, clinically unproven — rather than as a settled property of the molecule.

Research Models and How Lipogenesis Is Actually Measured

Understanding how AOD-9604 has been studied clarifies both what the data can support and what a real antilipogenic investigation would require. The methodology falls into three tiers, and only the first touches lipogenesis directly.

Ex vivo and in vitro fat-tissue work. The foundational studies examined lipolysis and lipogenesis in adipose tissue and isolated fat cells, measuring free-fatty-acid and glycerol release, fat oxidation, and — critically — the activity of lipogenic enzymes such as acetyl-CoA carboxylase.23 Enzyme-activity assays of this kind are the appropriate tool for an antilipogenic claim, and they are the source of the strongest evidence that a C-terminal domain peptide can suppress fat synthesis. A more complete modern program would add radiolabeled- or deuterium-tracer incorporation into fatty acids to quantify DNL flux, plus expression of ACC, FASN, SREBP-1c, and ChREBP under the peptide.

Rodent models. The most methodologically informative animal work is the β3-AR knockout study, a clean genetic approach that isolated the receptor’s contribution by comparing knockout and wild-type mice under identical treatment.4 Obese Zucker rats and ob/ob mice provided body-weight, fat-mass, and substrate-oxidation readouts.15 These are genetically obese metabolic models, well suited to whole-body fat-balance questions but blunt instruments for isolating lipogenesis from lipolysis, since net fat change reflects both.

Human trials. The clinical methodology was appropriate for an obesity drug — randomized, double-blind, placebo-controlled designs with weight and body-composition endpoints, plus dedicated safety and pharmacokinetic studies.610 A safety and tolerability study specifically characterized the peptide in humans.6 But none of these used lipogenesis endpoints. To answer this article’s question in humans would require a purpose-built study: stable-isotope measurement of de novo lipogenesis, adipose and hepatic lipogenic-gene expression, and controlled dosing — work that has never been done for AOD-9604.

The methodological bottom line is that the antilipogenic evidence is strongest exactly where it is least generalizable (isolated rodent fat-tissue enzyme assays) and absent exactly where it would matter most (human DNL flux). Until that gap is filled, any statement that AOD-9604 “reduces lipogenesis in humans” is hypothesis, not finding. Terminology used across this literature — lipogenesis, lipolysis, DNL, ACC, FASN — is defined for reference in the site’s peptide and metabolism glossary.

Safety and Tolerability

If there is one area where AOD-9604’s clinical record is relatively reassuring, it is short-term safety — a point that must be stated carefully, because “well tolerated in obesity trials” is not the same as “proven safe for repeated use,” and tolerability tells us nothing about efficacy.

In the human obesity program, AOD-9604 was generally reported to be well tolerated over the studied durations, without the endocrine concerns associated with full-length growth hormone. Specifically, it was reported not to elevate IGF-1 and not to impair glucose tolerance or insulin sensitivity in the settings studied — the effects it was engineered to avoid.1 A dedicated human safety and tolerability evaluation supported an acceptable short-term profile at the doses tested,6 and later characterization framed the ingredient as having a favorable safety and metabolism profile in the sponsor’s view.7

Several caveats temper this picture:

Efficacy is a separate question. A clean short-term safety profile says nothing about whether the compound reduces lipogenesis or produces meaningful fat loss; the pivotal obesity trial was safe and still failed on efficacy.10

Duration. Trials ran weeks to a few months; long-term safety of repeated administration is not characterized.

Route and formulation. The pivotal human work used oral dosing, whereas research and non-clinical use of reconstituted material is typically subcutaneous, and safety data do not transfer automatically across routes.

Product quality. Much material sold outside regulated channels is “research chemical” of variable purity; impurities, endotoxin, and mislabeling are real, sourcing-dependent risks.

Sport prohibition. AOD-9604 is prohibited in sport by the World Anti-Doping Agency; for athletes this is a regulatory hazard regardless of pharmacology.11

The reasonable reading is that AOD-9604 has not thrown up major short-term safety signals in the non-diseased populations studied, and its IGF-1-sparing profile avoids some GH-related concerns — but absence of demonstrated harm and absence of demonstrated efficacy can coexist, and here they do.

Handling and Reconstitution in a Research Context

Because AOD-9604 is most often encountered as a lyophilized (freeze-dried) powder in a sealed vial, a brief, strictly educational note on laboratory handling is warranted — with the emphasis that this is standard research-peptide practice, not a usage recommendation, and that AOD-9604 is not an approved therapeutic for any indication.

Lyophilized peptides are generally reconstituted with sterile or bacteriostatic water for laboratory purposes. The diluent is directed slowly against the inside wall of the vial rather than sprayed onto the powder, and the vial is gently swirled rather than shaken, because vigorous agitation can shear peptide bonds and denature the material. The volume of diluent chosen simply sets the concentration: a fixed mass of peptide dissolved in a larger volume yields a lower concentration per unit volume, the arithmetic underlying any reconstitution chart. Standard stability and storage considerations recur across the research-peptide literature.

Lyophilized storage

Cool, dark conditions; long-term stability favored by freezing

After reconstitution

Refrigerated; used within a limited window

Light and heat

Minimize exposure; both can degrade peptides

Agitation

Swirl gently; avoid shaking or foaming

Freeze-thaw

Repeated cycles degrade peptides; avoid

Sterility

Aseptic technique; bacteriostatic water for multi-use practice

It bears repeating that meticulous handling changes nothing about the evidence question. A perfectly reconstituted, high-purity vial of AOD-9604 is still a compound whose antilipogenic action is documented only preclinically and never quantified in humans. Good technique preserves whatever biological activity the molecule has; it does not create efficacy where none has been demonstrated. Researchers surveying how these compounds are cataloged can consult the site’s central dosages index, organized for educational reference rather than as guidance for human use.

Regulatory Status

AOD-9604’s regulatory picture is layered and frequently misrepresented, so precision matters.

No therapeutic approval, anywhere. AOD-9604 is not approved as a drug for obesity, metabolic disease, or any other condition by the U.S. Food and Drug Administration, the European Medicines Agency, or any comparable major regulator. Its pharmaceutical development for obesity was abandoned in 2007 after the pivotal trial failed to demonstrate a significant benefit over placebo.10 There is, correspondingly, no approved indication resting on its lipolytic or antilipogenic activity.

Supplement and food-ingredient framing. After the drug program ended, the compound was repositioned by its sponsor as a metabolic-health ingredient, supported by a self-affirmed “generally recognized as safe” (GRAS) characterization and safety/metabolism publications.7 It is essential to understand that a GRAS self-affirmation addresses ingredient safety at supplement-level exposure; it is emphatically not a finding of efficacy and not drug approval. A GRAS characterization tells you nothing about whether the peptide reduces lipogenesis or does anything useful metabolically — safety and efficacy are separate regulatory questions, and conflating them is one of the most common errors in the marketing literature around this compound.

U.S. compounding review. In 2024, AOD-9604 was among peptide substances considered by the FDA’s Pharmacy Compounding Advisory Committee for potential inclusion on the Section 503A bulk drug substances list. The committee voted against placing AOD-9604 on the list, citing inadequate physicochemical characterization, immunogenicity and impurity concerns, and a lack of clinical effectiveness data — a clear signal of continued regulatory caution about compounded peptide products.9

Anti-doping prohibition. The World Anti-Doping Agency has stated that AOD-9604 is prohibited in sport, falling under the categories covering growth factors and related substances. Athletes subject to WADA-compliant testing should assume that use will constitute an anti-doping rule violation.11

The regulatory synthesis is straightforward: AOD-9604 occupies an ambiguous middle ground — not an approved drug, variously handled as a supplement ingredient, unsettled in U.S. compounding, and banned in sport — with no regulatory recognition of any therapeutic use, let alone one based on reduced lipogenesis. Any legitimate exploration of the compound’s antilipogenic biology belongs in formal preclinical and clinical research under regulatory oversight, not off-label or informal use. Readers who want the companion mechanistic picture on the better-studied breakdown arm — the lipolytic counterpart to the fat-synthesis question examined here — can consult the site’s discussion of how AOD-9604 stimulates fat breakdown without altering IGF-1 pathways, which is the arm where the preclinical evidence is comparatively better characterized, in contrast to the thinner antilipogenic record that is the focus of this analysis.

Frequently Asked Questions

Does AOD-9604 actually reduce lipogenesis?

In preclinical models, there is real evidence pointing that way: a sibling C-terminal hGH analogue (AOD9401) inhibited acetyl-CoA carboxylase — the rate-limiting lipogenic enzyme — in rat adipose tissue, and C-terminal fragments have been described as “lipolytic and antilipogenic.”23 But this is rodent and isolated-tissue data. No human study has ever measured de novo lipogenesis under AOD-9604, so “reduces lipogenesis in humans” remains an untested hypothesis rather than a demonstrated fact.

What does “C-terminal growth hormone activity modulation” mean?

Full-length growth hormone does many things through its receptor, including raising IGF-1 and driving growth. Much of the hormone’s fat-metabolic activity was localized to its C-terminal region, and AOD-9604 is a stabilized peptide reproducing residues 176–191 of that region.1 “Modulation” means the fragment is designed to reproduce only the lipid-metabolic slice of GH activity while leaving the growth-promoting, IGF-1-raising receptor signaling behind — which is why it was repeatedly reported not to raise IGF-1.1

How is reducing lipogenesis different from stimulating lipolysis?

Lipolysis breaks stored triglyceride down into fatty acids for fuel; lipogenesis builds new fatty acids and triglyceride for storage. They are governed by different enzymes — hormone-sensitive lipase for breakdown, acetyl-CoA carboxylase and fatty acid synthase for synthesis.12 Most AOD-9604 coverage emphasizes the lipolytic arm; this article specifically examines the antilipogenic arm, where the evidence is thinner.

Is the antilipogenic effect the same as the β3-adrenergic effect?

Not exactly. The β3-adrenergic receptor knockout study shows β3-AR is necessary for the compound’s sustained lipolytic/weight effects, and AOD-9604 restores repressed β3-AR expression in obese fat tissue.4 But the direct antilipogenic readout — ACC inhibition — came from enzyme assays, so the two mechanisms are related but not identical. β3 signaling drives fat breakdown; the enzyme data address fat synthesis.

Did AOD-9604 work for weight loss in humans?

Not convincingly. Across roughly six trials in more than 900 participants, an early 12-week study (METAOD005) suggested a modest benefit, but the pivotal 24-week randomized, double-blind, placebo-controlled trial (METAOD006) did not reach statistical significance at its primary endpoint, and obesity development was halted in 2007.10 None of these trials measured lipogenesis directly.

Why does AOD-9604 not raise IGF-1 the way growth hormone does?

Because it was engineered specifically to isolate the C-terminal lipid-metabolic domain away from the receptor signaling that drives IGF-1 and growth. In rodent and human studies it was reported not to elevate IGF-1 or impair insulin sensitivity, in contrast to intact growth hormone.1 This is central to the “activity modulation” concept and is also why it cannot borrow GH’s insulin-resistance route to suppress lipogenesis.

Is AOD-9604 approved or legal?

It is not approved as a drug for any condition by the FDA, EMA, or other major regulators. It has been handled as a supplement/food-type ingredient via a self-affirmed GRAS characterization (a safety framing, not efficacy or drug approval), was not recommended for the FDA’s 503A compounding bulks list in 2024, and is prohibited in sport by WADA.7911

Could AOD-9604 ever become a validated lipogenesis-lowering therapy?

It cannot be ruled out, but it would require work that has never been done: dedicated ACC/FASN and DNL-flux studies on AOD-9604 itself, then human trials using stable-isotope lipogenesis endpoints, all overcoming a pivotal obesity trial that already failed. Even purpose-built lipogenesis inhibitors have struggled clinically, so a fragment starting from preclinical, indirect data is a long shot.

References

Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146367. https://pubmed.ncbi.nlm.nih.gov/11146367/

Ng FM, Jiang WJ, Gianello R, Pitt S, Roupas P. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-298. PMID: 11116208. https://pubmed.ncbi.nlm.nih.gov/11116208/

Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 10950816. https://pubmed.ncbi.nlm.nih.gov/10950816/

Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/

Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-1449. PMID: 11673763. https://pubmed.ncbi.nlm.nih.gov/11673763/

Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. https://www.jofem.org/index.php/jofem/article/view/157

Moré MI, Kenley D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab. 2014;4(3):64-77. https://jofem.org/index.php/jofem/article/view/213/278

Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-433. PMID: 26275694. https://pubmed.ncbi.nlm.nih.gov/26275694/

U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) Briefing Document, 2024 (AOD-9604 review for Section 503A bulk drug substances). https://www.fda.gov/media/183584/download

The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study (obesity clinical program; development halted 2007). https://www.researchgate.net/publication/295313034

World Anti-Doping Agency. WADA statement on substance AOD-9604. https://www.wada-ama.org/en/news/wada-statement-substance-aod-9604

Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895-902. PMID: 24814684. https://pubmed.ncbi.nlm.nih.gov/24814684/

Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010;20(1):1-7. PMID: 19800274. https://pubmed.ncbi.nlm.nih.gov/19800274/

Educational and research-use disclaimer: This article is provided solely for scientific and educational purposes. AOD-9604 is not approved by the FDA, EMA, or any comparable regulator for the treatment, cure, or prevention of obesity or any other disease, and no human study has demonstrated that it reduces de novo lipogenesis. Its antilipogenic activity is documented only in preclinical (rodent and isolated-tissue) models, and its pivotal human obesity trial did not achieve statistical significance versus placebo. Nothing here is medical advice or a recommendation for human use. AOD-9604 is prohibited in sport by WADA. Any legitimate investigation of this compound should occur within properly authorized preclinical or clinical research under appropriate oversight. Readers should consult qualified professionals and applicable regulations before making any decisions.